Pharmacia

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, March 28, 2024
Transcoding, Internal medicine, Temple University Hospital, CFO, Oncology, Patient, RNA, University, Cancer, University of Pittsburgh, Yale School of Medicine, Baylor College of Medicine, Infection, Therapy, Harvard University, Interim, Muscular dystrophy, Yale University, Pharmacia, Pharmaceutical industry

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.

Key Points: 
  • BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.
  • Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University.
  • While at Pharmacia, Dr. Vlock ran the Celebrex Oncology program involving two pivotal clinical trials and over 3,500 patients.
  • Dr. Vlock initially will serve on a part-time basis through TransCode’s arrangement with BioBridges LLC, a life sciences consulting company.

ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager

Retrieved on: 
Monday, April 8, 2024
Health, Kerry Group, Growth, State university system, PFE, American Chemistry Council, DOW, Engineering, Buffalo Niagara, Michigan State University, Safety, Chemical engineering, Project Management Professional, Food, ACC, Corporation, Pharmacia

HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.

Key Points: 
  • HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.
  • Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units.
  • Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department.
  • "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief Executive Officer.

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Quotient, Thakeham, Alnylam Pharmaceuticals, CDMO, Birth, Labs, GSK plc, Pharmacy, University, Novartis, Dana–Farber Cancer Institute, IUD, University College London, Embryology, IND, MBA, Woman, Doctor of Philosophy, Intrauterine device, Therapy, Drug development, Allergan, Amersham plc, Takeda Oncology, Chief Justice of Hungary, Pharmacia, Birth control

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points: 
  • Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
  • An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
  • Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
  • With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

NSF Welcomes Dean Bergy and Nancy Lurker to Board of Directors

Retrieved on: 
Wednesday, January 3, 2024
Automotive Manufacturing, Food, Beverage, Manufacturing, Cosmetics, Retail, Transport, Research, Medical Devices, Consulting, Professional Services, Logistics, Supply Chain Management, Fitness & Nutrition, Science, Utilities, Energy, Health, Packaging, Chemicals, Plastics, Pharmacia, Seattle Pacific University, INC, Stryker Corporation, Audit committee, Management development, PDI, RTI, Business administration, Translational medicine, City, Harvard Business School, Certified Public Accountant, Stanford School, Novartis, University, NSF, Water, Public, Triple accreditation, Organization, Corporation, Management

NSF , the leading global public health and safety organization, today announced the appointment of Dean Bergy and Nancy Lurker to its Board of Directors.

Key Points: 
  • NSF , the leading global public health and safety organization, today announced the appointment of Dean Bergy and Nancy Lurker to its Board of Directors.
  • “Dean Bergy and Nancy Lurker are welcome additions to our NSF Board of Directors,” said Pedro Sancha, President and CEO, NSF.
  • He also served on the board of directors of RTI Biologics, Inc. from 2010 to 2016, including as the Board Chair and Audit Committee Chair.
  • In joining the NSF Board of Directors, I look forward to supporting this impactful work.”
    Lurker is recognized for her diverse experience in the pharmaceutical and biotechnology industries.

Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of Directors

Retrieved on: 
Wednesday, December 13, 2023
Pharmacia, NPO, Trust, Heitman, Trustee, Healthpeak Properties, National Association, Tyco International, Therapy, EGP, University, JCI, UE, Toll Brothers, PEAK, Bard (company), Management

FORT WASHINGTON, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE: TOL) ( TollBrothers.com ), the nation’s leading builder of luxury homes, today announced that Judith A. Reinsdorf and Katherine M. Sandstrom have joined the Company’s Board of Directors.

Key Points: 
  • FORT WASHINGTON, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE: TOL) ( TollBrothers.com ), the nation’s leading builder of luxury homes, today announced that Judith A. Reinsdorf and Katherine M. Sandstrom have joined the Company’s Board of Directors.
  • She is also on the Board of Trustees of the University of Rochester and the board of the New Jersey Chapter of the National Association of Corporate Directors.
  • Douglas C. Yearley, Jr., chairman and chief executive officer, stated: “We are very pleased and excited to welcome both Judy and Kathy to the Toll Brothers Board of Directors.
  • We wish him all the best and are deeply appreciative of his many years of distinguished service to Toll Brothers.”

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Retrieved on: 
Tuesday, November 21, 2023
Pharmacia, Science, Cancer, Pharmacy, Commercial, AstraZeneca, Spacecraft, Health, SAN, Columbia University, STRO, Genentech, Growth, Patient, ADC, Onyx, Nursing

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the promotion of Jane Chung to President and Chief Operating Officer, a newly created role, effective December 1, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the promotion of Jane Chung to President and Chief Operating Officer, a newly created role, effective December 1, 2023.
  • In this newly created position, Ms. Chung will be responsible for driving operational excellence, strategic growth, and overall business success at Sutro.
  • “I am pleased to promote Jane into the leadership position created to optimize business operations at Sutro, expanding her role beyond the Commercial function.
  • “During her time at Sutro, Jane has demonstrated her invaluable strategic thinking skills and collaborative nature, making her the ideal candidate for this role.

Proxygen Announces Formation of Scientific Advisory Board

Retrieved on: 
Wednesday, November 15, 2023
MSD, DRS, Broad Institute, DNA, Limited partnership, National academy, Dana–Farber Cancer Institute, Patient, Research, Ubiquitin, Pharmacology, Therapy, Chromatin, Pioneer, Drug discovery, Cancer, Diabetes, Harvard University, Field, Howard Hughes Medical Institute, Translation, Organization, MIT, European, Jude the Apostle, Merck & Co., Austrian Academy of Sciences, Max Planck Society, Translational medicine, Leibniz Prize, JDRF, Pancreatic cancer, Ernst Jung Prize, Biochemistry, SAB, EMBO, Publishing, Louis-Jeantet Prize for Medicine, Pharmacia, Glioblastoma, Boehringer Ingelheim, Medicine, Biotechnology, Genomics, Doctor of Philosophy, Monroe Dunaway Anderson, Biology, DNA repair, Pharmaceutical industry, Science, Merck

VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB). The newly appointed SAB, which is comprised of highly regarded thought leaders in the emerging field of protein degradation, will offer scientific expertise and guidance to Proxygen as the company works to advance its internal molecular glue degrader programs toward clinical development. In addition to its internal programs, Proxygen is also actively engaged in strategic research collaboration and license agreements with Merck & Co (known as MSD outside the U.S. and Canada), Boehringer Ingelheim and Merck KGaA designed to jointly identify and develop novel molecular glue degraders.

Key Points: 
  • SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine
    VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB).
  • Schulman and Draetta to the Proxygen team as key advisors and pair them with Drs.
  • Winter and Kubicek, who co-founded the company, based on their trailblazing research at CeMM,” said Bernd Boidol, Ph.D., chief executive officer of Proxygen.
  • By streamlining and fully integrating cutting-edge genomic, proteomic, and biochemical technologies, Proxygen has successfully developed a highly versatile glue degrader discovery engine.

K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer

Retrieved on: 
Wednesday, November 15, 2023
NDA, Multiple myeloma, Pharmacia, Pfizer, Bristol Myers Squibb, Senior, Therapy, Clinical trial, MUSC, Patient, Communication, Medicine, Clinical research, Prostate cancer, Schering-Plough, Kite Pharma, MD, Drug discovery, Allogeneic processed thymus tissue, BMS, Doctor of Philosophy, Health, Drug, BCMA, Lava, ChromeOS, Translational medicine, GSK plc, Medical imaging, Pharmaceutical industry, Management, Celgene, Temozolomide, K36

CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams. Dr. Winograd joins K36 with a wealth of experience and a remarkable track record of bringing innovative medicines for hematological and solid tumor disease treatments to patients.

Key Points: 
  • Additional industry veterans recruited to strengthen clinical, translational medicine and preclinical teams
    CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- K36 Therapeutics, Inc .
  • ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams.
  • "Recruiting a leader with Dr. Winograd's expertise, reputation and track record of advancing transformative therapies validates the potential opportunity that KTX-1001 will deliver," said Terry Connolly, PhD, President and Chief Executive Officer of K36.
  • Most recently, Dr. Winograd was the Chief Medical Officer at Lava Therapeutics B.V. Dr. Winograd brings over 30 years of industry experience to K36, and will lead clinical development, translational medicine, regulatory affairs, and medical affairs.

Masimo Announces New Member of the Board of Directors

Retrieved on: 
Tuesday, November 7, 2023
Medical Devices, Health, Technology, Health Technology, Cardiology, Auxilium, Pharmacia, Mayo Collaborative Services v. Prometheus Laboratories, Inc., BICO Group, Catalent, Chemical engineering, MASI, Chemical substance, Vice, Business, Perrigo, Central Executive Committee of the Pakistan Peoples Party, Merck Millipore, Supervisory board, Gothenburg University Library, Executive Committee, University of Gothenburg, Gothenburg School of Business, Economics and Law, Retirement, Management, Engineering

Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.
  • Mr. Classon is an experienced medical technology executive and board member.
  • Mr. Classon was previously Chairman of the Board of Directors of Perrigo Company plc, Chairman of the Board of Directors of Tecan Group Ltd., Chairman of the Board of Directors of Hill-Rom Corporation, and Chairman of the Board of Directors of Auxilium Pharmaceuticals, Inc.
  • Joe Kiani, Chairman and CEO of Masimo, said, “We’re happy to welcome Rolf to our Board.

Actinium Appoints Lynn Bodarky as Chief Business Officer

Retrieved on: 
Friday, November 3, 2023
ACT, Pharmacia, CRADA, Bone marrow, NCI, NYSE, Columbia Business School, Kite Pharma, Rare, Precigen, Vaccine, BS, Business development, Genetics, Seagen, Wharton School of the University of Pennsylvania, Merck, University, Acquisition, MBA, Prostate cancer, Pfizer, Novartis, Geron Corporation, Neuroscience, Business, Immunotherapy, NIH, Autoimmunity, PSMA, Patient, Marketing, Pharmaceutical industry, Methylnaltrexone, Actinium

NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that Lynn Bodarky has been named Chief Business Officer to lead the Company's business development, licensing, and collaboration activities. Ms. Bodarky joins Actinium with over 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies including Pfizer, Merck, Progenics and HiFiBiO. Over her career, she has executed a wide array of business transactions totaling over $5 billion in value across oncology, autoimmune and neurological indications.

Key Points: 
  • NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that Lynn Bodarky has been named Chief Business Officer to lead the Company's business development, licensing, and collaboration activities.
  • Ms. Bodarky joins Actinium with over 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies including Pfizer, Merck, Progenics and HiFiBiO.
  • Ms. Bodarky joins Actinium from HiFiBiO Therapeutics, a clinical-stage biotechnology company developing immunotherapies for oncology and autoimmune diseases, where she was Senior Vice President, Global Head of Business Development & Operations.
  • "I am incredibly excited to join Actinium given the numerous near- and longer-term business development opportunities.